RxDoctor Payments Data

Jocelyn Eslick, NP

Family · Tulsa, OKNPI 1730725649

Payments from drug & device makers

$4,309in general payments, 2019–2025

Across 106 payments — averaging $40.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$729
  • Janssen Scientific Affairs, LLC$568
  • AstraZeneca$537
  • GSK$437
  • Sanofi$243
  • plus $596 from 4 others

What the payments were for

  • Food & beverage$4,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen26$1,199
AbbVie39$729
Janssen Scientific Affairs, LLC5$568
AstraZeneca10$537
GSK10$437
Sanofi2$243
UCB, Inc.4$201
Johnson & Johnson5$184
Lundbeck LLC2$150
Novartis3$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,309 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$368,690
Medicare patients
219
Services billed
30,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept182$1,483,916
Humira(Cf) PenAdalimumab89$1,078,276
OtezlaApremilast54$278,211
TremfyaGuselkumab20$274,608
RinvoqUpadacitinib31$209,490
EnbrelEtanercept26$201,437
Humira PenAdalimumab16$165,079
RemicadeInfliximab27$119,993
BenlystaBelimumab22$105,529
Orencia ClickjectAbatacept12$68,694
OrenciaAbatacept/Maltose11$49,568
Actemra ActpenTocilizumab12$31,264
Hydroxychloroquine Sulfate391$23,611
ActemraTocilizumab12$19,472
Leflunomide172$12,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$1,199$479,64880 claims
Johnson & JohnsonTremfya, Remicade$184$394,60147 claims
AbbVieRinvoq$729$209,49031 claims
GSKBenlysta$437$105,52922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →